KCNN4 and central nervous system cancer: Given the correlation between KCa3.1 overexpression in glioma patients and their poor survival rate (Hausmann et al. (2023) [71]), it is reasonable to consider targeting KCa3.1 as a means of reducing glioma invasiveness and progression.